Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

physicians an important new disease management option that might reduce the need for further therapeutic intervention after a defined treatment period."

Registration Studies for New Drug Application (NDA)

The clevudine Phase 3 registration program includes two 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Clevudine Study 305 will enroll approximately 376 chronic hepatitis B e-antigen positive patients (HBeAg+), and clevudine Study 306 will enroll approximately 480 chronic hepatitis B e-antigen negative patients (HBeAg-). Pharmasset plans to submit the 48-week data from these studies to the FDA as the basis for clevudine marketing approval.

The primary endpoint for the registration studies is a composite endpoint measuring the proportion of patients with both undetectable serum HBV DNA and normalized liver enzyme (ALT) levels following 48 weeks of monotherapy. The registration studies will also assess improvement in liver histology, hepatitis B e-antigen (eAg) seroconversion, decreases in the reservoir of HBV hepatic cccDNA, and quantitative eAg and surface antigen (sAg). The clevudine registration studies will be conducted in the United States, Canada, Brazil, the United Kingdom, Spain, Greece, Turkey, Romania, Czech Republic, Australia, New Zealand, Singapore, Hong Kong and Taiwan. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information about the clevudine registration studies.

Assessment of SVR for HBV

After the primary registration data have been obtained at week 48, the Phase 3 studies will continue to week 96 to gather additional safety and efficacy data, as well as to assess clevudine's sustained virologic response (SVR) rate for HBV. SVR is a measure of undet
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Calif. , June 19, 2013 Pharmacyclics, ... announced that The New England Journal of Medicine ... 2 study evaluating the investigational oral Bruton,s tyrosine kinase ... lymphoma (MCL) online. These data suggested ibrutinib may be ... Results of a separate study examining ...
(Date:6/19/2013)...  Haemonetics Corporation (NYSE: HAE ) ... of its previously announced manufacturing transformation.  ... , Haemonetics has selected Sanmina Corporation (NASDAQ: ... medical devices currently manufactured in Braintree ... of integrated manufacturing solutions, components, products and repair, ...
(Date:6/19/2013)... YORK , June 19, 2013 /PRNewswire-iReach/ -- ... pioneer of modern hair transplant procedures and founder ... was included in the ,Best Doctors, issue of ... (Photo:  http://photos.prnewswire.com/prnh/20130619/CG34629 ) ... Best Doctors issue, and his reputation as world-renowned ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
(Date:6/19/2013)... As warmer weather arrives and vacations begin, Asheville’s ... summertime packages. , “Whether guests are traveling to Asheville ... staycation, we think that these available packages will offer ... so beautiful in the summertime and there is a ... can choose from, based on their interests, offers something ...
(Date:6/19/2013)... 2013 According to Fastcare ... sun exposure is perhaps the biggest and certainly ... that is just one of many potential factors ... cancer. Other risk factors include:, , ... ,     Heredity may play a role , ...
(Date:6/19/2013)... The benefits, NASS said, ... the overall experience for the majority of those who ... Mr Mouw, whose Virgina-based company enjoys an international clientele, ... saying that the type of sauna is also important. ... counterfeit imitations which frankly, can be extremely dangerous particularly ...
(Date:6/19/2013)... Hollywood, CA (PRWEB) June 19, 2013 ... conditions with little to no access to the medical ... organizations are providing access to health care and the ... of these third-world nations. , Outlook with ... organizations to reveal the conditions in which these people ...
(Date:6/19/2013)... 19, 2013 Daily Gossip issued a press ... method will be published on their website at the ... article to inform readers about the information they will find ... reporters working at Daily Gossip, the article is a review ... , Hiller has understood during the vast research he has ...
Breaking Medicine News(10 mins):Health News:Fun Depot Partners with Brookstone Lodge on Summer Packages 2Health News:Risk Factors of Skin Cancer & Reducing That Risk 2Health News:Risk Factors of Skin Cancer & Reducing That Risk 3Health News:Health Benefits of Saunas Only Viable with Properly Constructed Models, Warns Manufacturer 2Health News:The Jump Manual Review: Reveals Hiller’s Method of Vertical Jump Training 2
... , DENVER, CO , Jan. 28 ... MIT is pleased to announce that it has started ... Jacques Gauthier and Mr. Michel Carrier as members ... has served on the board of directors of Axcan Pharma ...
... , Emergency Relief Fund Established for Haitian ... 28 The Assisted Living Federation of America ... Haitian employees of senior living companies. , "The employees of our ... seniors.  Now, in their hour of need, we offer support to ...
... CAMBRIDGE, Mass. , Jan. 28 DNA ... health through innovation, today announced it has been awarded ... from the National Aeronautics and Space Administration (NASA).  The ... facilitate whole health analysis in a single drop of ...
... part in a study thought that their obese four or five ... fathers, according to the February issue of Acta Paediatrica . ... of mothers and 77 per cent of fathers thought that their ... children took part in the study, carried out by researchers from ...
... innovative cardiac scanner will dramatically improve the process of ... developed at the University of Leeds, with funding from ... a key role. Due to its unprecedented ... to detect a number of conditions, including heart problems ...
... , ... Attempt, George Hood Utilizes Blogging, Facebook, Twitter, and LinkedIn to Raise Awareness, Funds ... Aurora, IL (PRWEB) January 28, ... Ultra endurance athlete is currently training to break the Guinness world record in stationary (spin) ...
Cached Medicine News:Health News:MIT is pleased to announce the nomination of Mr. Jacques Gauthier and Mr. Michel Carrier to its newly formed Advisory Board 2Health News:ALFA Extends Helping Hand to Haiti 2Health News:NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR 2Health News:Most parents don't realize their 4 or 5 year-olds are overweight or obese 2Health News:Breakthrough heart scanner will allow earlier diagnosis 2Health News:Aurora Man's Guinness World Record Attempt Goes Social 2Health News:Aurora Man's Guinness World Record Attempt Goes Social 3Health News:Aurora Man's Guinness World Record Attempt Goes Social 4
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: